Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1). Canakinumab is a human monocl...

Source: Pediatric Rheumatology - July 8, 2019 Category: Rheumatology Authors: Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins and Paul Brogan Tags: Research article Source Type: research